Prevention and management of cytomegalovirus infection in solid-organ transplantation

Authors: Mwintshi, Kabeya; Brennan, Daniel C

Source: Expert Review of Anti-Infective Therapy, Volume 5, Number 2, April 2007 , pp. 295-304(10)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Cytomegalovirus (CMV) is the most common opportunistic viral infection to occur following solid-organ transplantation. This review will discuss the current strategies of management of CMV in solid-organ transplantation and their challenges. There are two principal approaches for preventing CMV disease in recipients of solid-organ transplants: prophylactic and pre-emptive. Ganciclovir is the most studied and used antiviral for both treatment and prevention, and is the first-line treatment for CMV infection and CMV disease in transplant recipients. There is no consensus regarding the most appropriate prevention method and the approach to CMV disease prevention differs among transplantation centers owing to the paucity of data comparing the two strategies head-to-head. Currently, the recommended treatment for CMV disease is intravenous ganciclovir.

Keywords: cytomegalovirus; management; prevention; solid organ transplant

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14787210.5.2.295

Publication date: 2007-04-01

More about this publication?

Expert Review of Anti-infective Therapy provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites